Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Dow
Moodys
Medtronic

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Infliximab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for infliximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Shanghai Mental Health CenterN/A
National Institute for Tuberculosis and Lung Diseases, PolandPhase 4
Hull and East Yorkshire Hospitals NHS TrustPhase 2

See all infliximab clinical trials

Recent Litigation for infliximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. CIPLA LIMITED2019-07-03

See all infliximab litigation

PTAB Litigation
PetitionerDate
Dr. Reddy's Laboratories, Inc.2018-08-03

See all infliximab litigation

Pharmacology for infliximab

Patent Text Search: US Patents for infliximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for infliximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00717 Netherlands   Start Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
2017009 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703
0868 Netherlands   Start Trial PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707
2017 00012 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
C/GB10/044 United Kingdom   Start Trial PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
Dow
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.